POSTED TO CSE

July 2, 2019

Canadian Securities Exchange
First Canadian Place
100 King Street West, Suite 7210
Toronto, ON M5X 1E1

Dear Sirs/Mesdames:

RE: Cannvas MedTech Inc. (the "Company")
Option Cancellations

This letter is to confirm the cancellation of the following options that were granted on February 6, 2018, August 15, 2018 and November 6, 2018.

Name of Optionee	Number of Options Granted	Exercise Price	Date Granted	Date Cancelled
Simon Yaylagul	50,000	$0.25	February 6, 2018	July 3, 2019
Marianne Musi	25,000	$0.25	February 6, 2018	July 3, 2019
Kay Capital	100,000	$0.25	February 6, 2018	July 3, 2019
Nebil Yaylagul	35,000	$0.25	February 6, 2018	July 3, 2019
Elizabeth Moniz	50,000	$0.34	August 15, 2018	July 3, 2019
Tom Loutskou	50,000	$0.34	August 15, 2018	July 3, 2019
Khavita Harrycharran	100,000	$0.34	August 15, 2018	July 3, 2019
Ben Feist	25,000	$0.34	August 15, 2018	July 3, 2019
Kay Capital	250,000	$0.37	November 6, 2018	July 3, 2019
Mile End Creative	250,000	$0.37	November 6, 2018	July 3, 2019
TOTAL:	**935,000**			

We are attaching the Form 11s *Notice of Proposed Stock Option Grant or Amendment* for August 15, 2018 and November 6, 2018. The Company was not listed for trading on the Canadian Securities Exchange at the time of the February 6, 2018 grant and, therefore, no Form 11 *Notice of Proposed Stock Option Grant or Amendment* was prepared.

Yours truly,

CANNVAS MEDTECH INC.

"Steve Loutskou"

Steve Loutskou,
COO

AMENDED
FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **Cannvas MedTech Inc.** (the "Issuer").

Trading Symbol: **MTEC**

Date: **July 2, 2019**

1. New Options Granted:

Date of Grant: **August 15, 2018**

The options highlighted in yellow have been cancelled effective July 2, 2019.

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Elizabeth Moniz	Consultant	N	50,000	$0.34	Aug. 15/20	Nil
Tom Loutskou	Consultant	N	50,000	$0.34	Aug. 15/20	Nil
Khavita Harrycharran	Consultant	N	100,000	$0.34	Aug. 15/20	160,000
Ben Feist	Consultant	N	25,000	$0.34	Aug. 15/20	Nil
TOTAL OPTIONS CANCELLED:			**175,000**			
Daniel Davidzon	Consultant	N	10,000	$0.34	Aug. 15/20	Nil
Benny Maghilom	Consultant	N	10,000	$0.34	Aug. 15/20	10,000
Remi Roy	Consultant	N	20,000	$0.34	Aug. 15/20	Nil
Daniel DelFavro	Consultant	N	10,000	$0.34	Aug. 15/20	Nil
Stacy Paterson	Consultant	N	25,000	$0.34	Aug. 15/20	Nil
Dr. Shirish Patel	Consultant	N	25,000	$0.34	Aug. 15/20	Nil

Total Number of optioned shares proposed for acceptance: **N/A**

2. Other Presently Outstanding Options:

3,827,000 options as at July 2, 2019.

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

N/A.

(b) State the date of the news release announcing the grant of options.

N/A.

(c) State the total issued and outstanding share capital at the date of grant or amendment.

43,314,461 common shares as at August 15, 2018.

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

7.52% as at July 2, 2019.

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

N/A.

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

N/A.

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

N/A.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated July 2, 2019.

Shawn Moniz
Name of Director or Senior Officer

"Shawn Moniz"
Signature

CEO and Director
Official Capacity

AMENDED
FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: **Cannvas MedTech Inc.** (the "Issuer").

Trading Symbol: **MTEC**

Date: **July 2, 2019**

1. New Options Granted:

Date of Grant: November 6, 2018

The options highlighted below have been cancelled effective July 2, 2019.

Name of Optionee	Position with Issuer	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Kay Capital	Consultant	N	250,000	$0.37	Nov. 6/19	100,000
Mile End Creative	Consultant	N	250,000	$0.37	Nov. 6/19	Nil
TOTAL OPTIONS CANCELLED:			**500,000**			
Benny Maghilom	Consultant	N	10,000	$0.37	Nov. 6/19	20,000
Remi Roy	Consultant	N	20,000	$0.37	Nov. 6/19	20,000
Sandra Rahmoun	Consultant	N	50,000	$0.37	Nov. 6/19	Nil
Lindsay Hamelin	Director	N	50,000	$0.37	Nov. 6/19	50,000

Total Number of optioned shares proposed for acceptance: **N/A**

2. Other Presently Outstanding Options:

3,827,000 options as at July 2, 2019.

3. Additional Information

(a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

N/A.

(b) State the date of the news release announcing the grant of options.

November 6, 2018.

(c) State the total issued and outstanding share capital at the date of grant or amendment.

44,674,461 common shares as at November 6, 2018.

(d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

7.52% as at July 2, 2019.

(e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

N/A.

(f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

N/A.

(g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

N/A.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated July 2, 2019.

Shawn Moniz
Name of Director or Senior Officer

"Shawn Moniz"
Signature

CEO and Director
Official Capacity